Authentification abonné
medsci
Accueil Tous les numéros Volume 27 / Numéro 8-9 (Août–Septembre 2011) Med Sci (Paris), 27 8-9 (2011) 725-732 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 8-9, Août–Septembre 2011
Page(s) 725 - 732
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011278014
Publié en ligne 31 août 2011
  1. Ray-Gallet D, Gérard A, Polo S, Almouzni G. Variations sur le thème du « code histone ». Med Sci (Paris) 2005 ; 21 : 384-389. [CrossRef] [EDP Sciences] [PubMed]
  2. Kouzarides T. Chromatin modifications and their function. Cell 2007 ; 128 : 693-705. [CrossRef] [PubMed]
  3. Mottet D, Castronovo V. Les histone désacétylases. Nouvelles cibles pour les thérapies anti-cancéreuses. Med Sci (Paris) 2008 ; 24 : 742-6. [CrossRef] [EDP Sciences] [PubMed]
  4. Sowa Y. Development of HDAC inhibitors. Gan To Kagaku Ryoho 2010 ; 37 : 1665-1668. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  5. Albert M, Helin K. Histone methyltransferases in cancer. Sem Cell Dev Biol 2010 ; 21 : 209-220. [CrossRef]
  6. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002 ; 12 : 198-209. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  7. Schneider R, Bannister AJ, Kouzarides T. Unsafe SET: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002 ; 27 : 396-402. [CrossRef] [PubMed]
  8. Peters AH, O’Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001 ; 107 : 323-337. [CrossRef] [PubMed]
  9. Czvitkovich S, Sauer S, Peters AH, et al. Over-expression of the SUV39H1 histone methyltransferase induces altered proliferation and differentiation in transgenic mice. Mech Dev 2001 ; 107 : 141-153. [CrossRef] [PubMed]
  10. Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001 ; 412 : 561-565. [CrossRef] [PubMed]
  11. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001 ; 8 : 1487-1503. [PubMed]
  12. Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 2008 ; 105 : 344-352. [CrossRef] [PubMed]
  13. Carbone R, Botrugno OA, Ronzoni S, et al. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 2006 ; 26 : 1288-1296. [CrossRef] [PubMed]
  14. Goyama S, Nitta E, Yoshino T, et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 2010 ; 24 : 81-88. [CrossRef] [PubMed]
  15. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007 ; 7 : 823-833. [CrossRef] [PubMed]
  16. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001 ; 20 : 5695-5707. [CrossRef] [PubMed]
  17. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003 ; 17 : 2298-2307. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  18. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005 ; 121 : 167-178. [CrossRef] [PubMed]
  19. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007 ; 21 : 525-530. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  20. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002 ; 419 : 624-629. [CrossRef] [PubMed]
  21. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005 ; 18 : 263-272. [CrossRef] [PubMed]
  22. Cheung N, Chan LC, Thompson A, et al. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007 ; 9 : 1208-1215. [CrossRef] [PubMed]
  23. Majumder S, Liu Y, Ford OH, et al. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. The Prostate 2006 ; 66 : 1292-1301. [CrossRef] [PubMed]
  24. Greiner D, Bonaldi T, Eskeland R, et al. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005 ; 1 : 143-145. [CrossRef] [PubMed]
  25. Cook KM, Hilton ST, Mecinovic J, et al. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 2009 ; 284 : 26831-26838. [CrossRef] [PubMed]
  26. Isham CR, Tibodeau JD, Jin W, et al. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007 ; 109 : 2579-2588. [CrossRef] [PubMed]
  27. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007 ; 21 : 1050-1063. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  28. Kubicek S, O’Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007 ; 25 : 473-481. [CrossRef] [PubMed]
  29. Cheng D, Yadav N, King RW, et al. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 2004 ; 279 : 23892-23899. [CrossRef] [PubMed]
  30. Spannhoff A, Machmur R, Heinke R, et al. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 2007 ; 17 : 4150-4153. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.